Thromboprophylaxis with nadroparin in the orthopaedic setting, a brief appraisal of the recent literature

Article Sidebar

PDF Download
Published Feb 15, 2018
DOI: https://doi.org/10.18103/mra.v6i2.1654

Downloads

Download data is not yet available.

Submit your own article

Register as an author to reserve your spot in the next issue of the Medical Research Archives.

Author Registration

Join the Society

The European Society of Medicine is more than a professional association. We are a community. Our members work in countries across the globe, yet are united by a common goal: to promote health and health equity, around the world.

Join Europe’s leading medical society and discover the many advantages of membership, including free article publication.

Membership

Main Article Content

Alberto Farina Davide Imberti Alessandro Alonzi Rossana Cecchi

Abstract

Low-molecular-weight heparins represent well-established agents for thromboprophylaxis in the orthopaedic and traumatological setting. The availability of different compounds requires the doctor to make a careful choice especially in the dose and duration of treatment, which represent two key factors for a successful therapy. In addition to the clinical benefit for the patient, an appropriate therapeutic choice allows the physician not to incur in medico-legal implications. In the present paper, we briefly review recent data from new trials in which nadroparin was used in patients after knee arthroscopy and lower leg plaster cast, and discuss the mode of use of the drug and the potential medico-legal implications.

Keywords: Low-molecular-weight heparins;, nadroparin, orthopaedics and traumatology, legal medicine

Article Details

How to Cite
FARINA, Alberto et al. Thromboprophylaxis with nadroparin in the orthopaedic setting, a brief appraisal of the recent literature. Medical Research Archives, [S.l.], v. 6, n. 2, feb. 2018. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/1654>. Date accessed: 14 nov. 2024. doi: https://doi.org/10.18103/mra.v6i2.1654.
ABNT APA BibTeX CBE EndNote - EndNote format (Macintosh & Windows) MLA ProCite - RIS format (Macintosh & Windows) RefWorks Reference Manager - RIS format (Windows only) Turabian
Issue
Vol 6 No 2 (2018): Vol.6 Issue 2 February 2018
Section
Research Articles

The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.

 

References

1. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schuünemann HJ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141(2 Suppl):7S-47S.

2. Randelli F, Romanini E, Biggi F, Danelli G, Della Rocca G, Laurora NR, Imberti D, Palareti G, Prisco D. II Italian intersociety consensus statement on antithrombotic prophylaxis in orthopaedics and traumatology: arthroscopy, traumatology, leg immobilization, minor orthopaedic procedures and spine surgery. J Orthop Traumatol. 2013;14(1):1-13.

3. Davis R, Faulds D. Nadroparin calcium. A review of its pharmacology and clinical use in the prevention and treatment of thromboembolic disorders. Drugs Aging. 1997;10(4):299-322.

4. Ageno W, Bosch J, Cucherat M, Eikelboom JW. Nadroparin for the prevention of venous thromboembolism in nonsurgical patients: a systematic review and meta-analysis. J Thromb Thrombolysis. 2016;42(1):90-8.

5 Agnelli G, Gussoni G, Bianchini C, Verso M, Mandalà M, Cavanna L, Barni S, Labianca R, Buzzi F, Scambia G, Passalacqua R, Ricci S, Gasparini G, Lorusso V, Bonizzoni E, Tonato M; PROTECHT Investigators. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 2009;10(10):943-9.

6. Charbonnier BA, Fiessinger JN, Banga JD, Wenzel E, d'Azemar P, Sagnard L. Comparison of a once daily with a twice daily subcutaneous low molecular weight heparin regimen in the treatment of deep vein thrombosis. FRAXODI group. Thromb Haemost. 1998;79(5):897-901.
.
7. van Adrichem RA, Nemeth B, Algra A, le Cessie S, Rosendaal FR, Schipper IB, Nelissen RGHH, Cannegieter SC; POT-KAST and POT-CAST Group. Thromboprophylaxis after Knee Arthroscopy and Lower-Leg Casting. N Engl J Med 2017;376(6):515-25.

8. Bruntink MM, Groutars YME, Schipper IB, Breederveld RS, Tuinebreijer WE, Derksen RJ; PROTECT studygroup. Nadroparin or fondaparinux versus no thromboprophylaxis in patients immobilised in a below-knee plaster cast (PROTECT): A randomised controlled trial. Injury. 2017;48(4):936-40.

9. Chapelle C, Rosencher N, Jacques Zufferey P, Mismetti P, Cucherat M, Laporte S; Meta-Embol Group. Prevention of venous thromboembolic events with low-molecular-weight heparin in the non-major orthopaedic setting: meta-analysis of randomized controlled trials. Arthroscopy. 2014;30(8):987-96.
10. Sun Y, Chen D, Xu Z, Shi D, Dai J, Qin J, Qin J, Jiang Q. Deep venous thrombosis after knee arthroscopy: a systematic review and meta-analysis. Arthroscopy. 2014;30(3):406-12.

11. Nadroparin (Seleparina) Summary of Product Characteristics.

12. Leyvraz PF, Bachmann F, Hoek J, Buller HR, Postel M, Samama M, Vandenbroek MD. Prevention ofdeep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ. 1991;303:543-8.

13. Pascale W, Mineo G, Pascale V. Prevention of venous thromboembolism after knee arthroscopy: six-year experience with the low molecular weight nadroparin calcium. Minerva Ortop Traumatol. 2007;58(5):347-52.